Healthcare Market Research Reports | Custom Research

Healthcare

Rosai-Dorfman Disease Treatment Market By Treatment Type (Drug Therapy, Surgical Treatment, Radiation Therapy); By Drug Class (Targeted Therapeutics, Corticosteroids, Chemotherapeutic Agents, Other Systemic Agents); By Disease Presentation (Extranodal Rosai-Dorfman Disease, Nodal Rosai-Dorfman Disease, Multisystem Rosai-Dorfman Disease); By Treatment Setting (Outpatient Treatment, Inpatient Treatment, Ambulatory Care); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Rosai-Dorfman Disease Treatment Market: How Are Recurrence and Molecular Treatment Selection Shaping Revenue?

According to Strategic Market Research, the global Rosai-Dorfman Disease Treatment Market was valued at approximately USD 38.28 million in 2025 and is project... Read More

Refsum Disease Treatment Market By Treatment Type (Dietary Management, Plasma Exchange Therapy, Symptomatic and Supportive Treatment); By Disease Type (PHYH-Related Classic Refsum Disease, PEX7-Related Classic Refsum Disease, Infantile Refsum Disease); By Age Group (Pediatric Patients, Adults, Geriatric Patients); By End User (Hospitals, Specialty Clinics, Home Healthcare Settings); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialized Medical Nutrition Suppliers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Refsum Disease Treatment Market: How Are Earlier Diagnosis and Lifelong Metabolic Care Shaping Treatment Spending?

According to Strategic Market Research, the Global Refsum Disease Treatment Market was valued at USD 6.30 million in 2025 and is projected to reach USD 1... Read More

Laron Syndrome Market By Treatment Type (Recombinant IGF-1 Therapy, Supportive Care, Emerging Therapies); By Diagnosis Type (Genetic Testing, Hormonal Assays, Clinical Assessment); By Drug Type (Mecasermin, Investigational Therapies); By Route of Administration (Subcutaneous Injection, Other Routes); By Age Group (Pediatric Patients, Adolescent Patients, Adult Patients); By End User (Hospitals, Specialty Clinics, Diagnostic Laboratories); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Precision Diagnosis, Recombinant IGF-1 Therapy, and Emerging Treatments Shaping the Global Laron Syndrome Market?

According to Strategic Market Research, the Global Laron Syndrome Market was valued at USD 3.20 million in 2025 and is projected to reach USD 5.46... Read More

Carcinoid Syndrome Treatment Market By Treatment Type (Pharmacological Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Liver-Directed Therapy); By Drug Class (Somatostatin Analogs, Serotonin Synthesis Inhibitors, Interferon Therapy, Other Treatment Categories); By Route of Administration (Subcutaneous Administration, Intramuscular Administration, Oral Administration, Other Administration Routes and Procedural Interventions); By Symptom Type (Carcinoid Syndrome Diarrhea, Flushing, Bronchospasm, Other Symptoms and Complications); By End User (Hospitals, Specialty Oncology Centers, Homecare Settings); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Advanced Therapies and Expanding Neuroendocrine Tumor Care Shaping the Global Carcinoid Syndrome Treatment Market?

According to Strategic Market Research, the Global Carcinoid Syndrome Treatment Market was valued at USD 1.237 billion in 2025 and is projected t... Read More

Eisenmenger Syndrome Treatment Market By Treatment Type (Pharmacological Treatment, Surgical Treatment, Supportive Care); By Drug Class (Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin Therapies); By Route of Administration (Oral Administration, Intravenous Administration, Inhalation); By Underlying Heart Defect (Ventricular Septal Defect (VSD), Atrial Septal Defect (ASD), Patent Ductus Arteriosus (PDA)); By Patient Age Group (Pediatric Patients, Adults (18–60 Years), Geriatric Patients (Above 60 Years)); By End User (Hospitals, Specialty Cardiology Centers, Home Healthcare Settings); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Targeted Pulmonary Hypertension Therapies and Advanced Clinical Technologies Transforming the Eisenmenger Syndrome Treatment Market?

According to Strategic Market Research, the Global Eisenmenger Syndrome Treatment Market was valued at USD 208.7 million in 202... Read More

Craniopharyngioma Treatment Market By Treatment Type (Surgery, Radiation Therapy, Targeted Therapy); By Tumor Type (Adamantinomatous Craniopharyngioma, Papillary Craniopharyngioma); By End User (Hospitals, Specialty Neurosurgery Centers, Cancer Treatment Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Global Craniopharyngioma Treatment Market Evolving Across Surgical, Radiation, and Targeted Therapeutic Approaches?

The increasing use of specialized brain tumor surgery, radiation therapy, and long-term Read More

Moyamoya Disease Market By Disease Type (Ischemic Moyamoya Disease, Hemorrhagic Moyamoya Disease, Asymptomatic Moyamoya Disease); By Treatment (Surgical Treatment, Medical Treatment, Supportive Treatment); By Surgery (Direct Revascularization, Indirect Revascularization, Combined Revascularization); By Diagnosis (MRI/MRA, Digital Subtraction Angiography (DSA), CT Angiography (CTA)); By End User (Hospitals, Specialty Clinics, Diagnostic Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Moyamoya Disease Market: How Are Earlier Diagnosis and Cerebral Bypass Access Reshaping Specialized Care?

According to Strategic Market Research, the Global Moyamoya Disease Market was valued at USD 618.50 million in 2025 and is projected to reach USD 927.01 million b... Read More

Niemann-Pick Disease Type C Treatment Market By Treatment Type (Substrate Reduction Therapy, Arimoclomol-Based Therapy, Levacetylleucine Therapy, Supportive Treatment); By Drug Type (Miglustat, Arimoclomol, Levacetylleucine); By Patient Age Group (Pediatric Patients, Adult Patients); By Route of Administration (Oral Administration, Enteral Administration); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Targeted Therapies, Clinical Innovation, and Expanding Treatment Access Transforming the Global Niemann-Pick Disease Type C Treatment Market?

Increasing diagnosis of Niemann-Pick Disease Type C (NPC), growing demand for Read More

Rhabdomyosarcoma Treatment Market By Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, Immunotherapy); By Disease Subtype (Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma, Pleomorphic Rhabdomyosarcoma); By Age Group (Pediatric, Adolescent, Adult); By Treatment Setting (Hospitals, Specialty Cancer Centers, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Advanced Therapies and Pediatric Oncology Innovations Transforming the Rhabdomyosarcoma Treatment Market?

According to Strategic Market Research, the Global Rhabdomyosarcoma Treatment Market was valued at USD 532.60 million in 2025 and is projected to ... Read More

Published Date: Oct-2026 | No Of Pages:161 | $ 4485

Diamond-Blackfan Anemia Treatment Market By Treatment Type (Corticosteroid Therapy, Blood Transfusion Therapy, Hematopoietic Stem Cell Transplantation, Iron Chelation Therapy, Emerging Gene Therapies); By Patient Age Group (Pediatric Patients, Adult Patients); By End User (Hospitals, Specialty Hematology Clinics, Stem Cell Transplant Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Global Diamond Blackfan Anemia Treatment Market Evolving Through Clinical Management and Emerging Therapies?

The Global Diamond-Blackfan Anemia Treatment Market was valued at USD 155.62 million in 2025 and is projected to reach USD 235.36 million by 2032, g... Read More
Published Date: Oct-2026 | No Of Pages:156 | $ 4485

Wilms Tumor Treatment Market By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy); By Drug Class (Antitumor Antibiotics, Vinca Alkaloids, Alkylating Agents, Topoisomerase Inhibitors); By Disease Stage (Stage I, Stage II, Stage III, Stage IV, Stage V); By Histology (Favorable Histology, Anaplastic Histology); By Age Group (Below 2 Years, 2–5 Years, 6–10 Years, Above 10 Years); By End User (Hospitals, Specialty Cancer Centers, Pediatric Oncology Clinics); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Advanced Treatment Approaches Transforming the Global Wilms Tumor Treatment Market?

The use of multi-agent chemotherapy, nephrectomy, and risk-adapted treatment protocols for children diagnosed with Wilms tumor is shaping the global Wilms Tumor Treatment Marke... Read More
Published Date: Oct-2026 | No Of Pages:165 | $ 4485

Barth Syndrome Treatment Market By Treatment Type (Medication, Nutritional Support, Heart Transplantation, Investigational Therapies); By Diagnosis (Genetic Testing, Cardiac Testing, Biochemical Testing); By Clinical Manifestation (Cardiomyopathy, Neutropenia, Muscle Weakness, Growth Delay); By End User (Hospitals, Specialty Clinics, Research Institutes); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Barth Syndrome Treatment Market and How Is It Evolving?

The introduction of targeted therapies and continued demand for cardiac care, infection management, and supportive treatments are influencing the Barth syndrome treatment market. According to Strategi... Read More
Published Date: Oct-2026 | No Of Pages:149 | $ 4485

Lamellar Ichthyosis Treatment Market By Treatment Type (Topical Treatments, Systemic Treatments, Supportive Care); By Drug Class (Emollients and Moisturizers, Keratolytic Agents, Retinoids); By Route of Administration (Topical, Oral); By Age Group (Pediatric Patients, Adult Patients); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Lamellar Ichthyosis Treatment Market and How Is It Advancing Dermatological Care?

Lamellar ichthyosis is a rare inherited skin disorder requiring lifelong treatment to manage severe dryness, thick scaling, and associated complications. According to Strateg... Read More
Published Date: Oct-2026 | No Of Pages:151 | $ 4485

Porphyria Treatment Market By Disease Type (Acute Hepatic Porphyria, Porphyria Cutanea Tarda, Erythropoietic Protoporphyria, Other Porphyria Types); By Treatment Type (Drug Therapy [Excluding Hemin and RNAi Therapies], Hemin Therapy, RNAi Therapy, Phlebotomy, Supportive Care); By Route of Administration (Oral, Intravenous, Subcutaneous); By End User (Hospitals, Specialty Clinics, Other Healthcare Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Porphyria Treatment Market and How Is It Transforming Rare Disease Management?

The Global Porphyria Treatment Market was estimated at USD 533.61 million in 2025 and is projected to reach USD 956.94 million by 2032, growing at a CAGR of 8.75% from 2026 to 2... Read More
Published Date: Oct-2026 | No Of Pages:151 | $ 4485

Budd-Chiari Syndrome Treatment Market By Treatment Type (Anticoagulant Therapy, Thrombolytic Therapy, Angioplasty, Transjugular Intrahepatic Portosystemic Shunt [TIPS], Liver Transplantation); By Drug Class (Anticoagulants, Thrombolytics, Diuretics, Beta-Blockers); By Disease Type (Acute Budd-Chiari Syndrome, Subacute Budd-Chiari Syndrome, Chronic Budd-Chiari Syndrome, Fulminant Budd-Chiari Syndrome); By Route of Administration (Oral, Intravenous, Subcutaneous); By End User (Hospitals, Specialty Clinics, Transplant Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Budd-Chiari Syndrome Treatment Market and How Is It Transforming Liver Disease Management?

The Global Budd-Chiari Syndrome Treatment Market was estimated at USD 363.19 million in 2025 and projected to reach USD 533.13 million by 2032, growing at a CAGR of ... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

Cryoglobulinemia Treatment Market By Treatment Type (Antiviral Therapy, Immunosuppressive Therapy, Biologic Therapy, Plasma Exchange); By Disease Type (Type I Cryoglobulinemia, Type II Cryoglobulinemia, Type III Cryoglobulinemia); By Route of Administration (Oral, Intravenous, Subcutaneous); By End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Care Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Cryoglobulinemia Treatment Market: How Are Targeted Biologics and Antiviral Therapies Shaping Growth?

The Global Cryoglobulinemia Treatment Market was estimated at USD 622.63 million in 2025 and is projected to reach USD 892.70 million by 2032, growing at a CAGR of 5.... Read More
Published Date: Oct-2026 | No Of Pages:161 | $ 4485

Granisetron Market By Dosage Form (Tablets, Injections, Transdermal Patches); By Application (Chemotherapy-Induced Nausea and Vomiting [CINV], Radiation-Induced Nausea and Vomiting [RINV], Postoperative Nausea and Vomiting [PONV]); By Route of Administration (Oral, Intravenous, Transdermal, Subcutaneous); By End User (Hospitals & Clinics, Oncology Centers, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Granisetron Market and How Is It Transforming Nausea and Vomiting Management?

The Global Granisetron Market was raised from USD 351.64 million in 2025 to USD 458.98 million by 2032, growing at a CAGR of 3.88%, according to Strategic Market Research. D... Read More
Published Date: OCT-2026 | No Of Pages:151 | $ 4485

Ropivacaine Market By Preparation / Formulation Type (Injectable Solutions, Topical / Emerging Formulations [Developmental Scenario]); By Concentration (2 mg/mL, 5 mg/mL, 7.5 mg/mL, Other Concentrations and Custom Volumes [Including 10 mg/mL]); By Application / Clinical Procedure (Orthopedic and Musculoskeletal Surgical Anesthesia, General and Abdominal Surgical Anesthesia, Obstetric and Gynecologic Surgical Anesthesia, Other Surgical Anesthesia Applications, Continuous Epidural Pain Management, Regional Nerve Blocks for Acute Pain, Postoperative Wound Infiltration and Multimodal Analgesia); By End User (Hospitals, Ambulatory Surgical Centers [ASCs], Specialty Clinics and Nursing/Rehabilitation Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Global Ropivacaine Market, and How Are Surgical Procedures and Regional Anesthesia Applications Supporting Growth?

The Global Ropivacaine Market was estimated at USD 588.70 million in 2025 and is projected to reach USD 851.50 million by 2032, expandin... Read More
Published Date: Oct-2026 | No Of Pages:151 | $ 4485

Second- & Third-Line Advanced Soft-Tissue Sarcoma Therapeutics Market By Treatment Line (Second-Line Treatment, Third-Line Treatment); By Histology (Dedifferentiated Liposarcoma, Myxoid Liposarcoma, High-Grade Myxoid/Round-Cell Liposarcoma, Pleomorphic Liposarcoma, Non-Uterine Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma); By Established Therapy (Trabectedin, Pazopanib, Eribulin, Other Systemic Options); By Treatment Administration (Intravenous Treatment, Oral Treatment, Intratumoral Treatment); By Geography (Asia, Europe, North America, Latin America, Middle East), Treatment Expenditure Estimation, Forecast, 2025–2035

How Large Is the Second- & Third-Line Advanced Soft-Tissue Sarcoma Therapeutics Market, and What Are Its Key Treatment Opportunities?

The Second- & Third-Line Advanced Soft-Tissue Sarcoma Therapeutics Market represented approximately USD 58.2 million in annual... Read More
Published Date: Oct-2026 | No Of Pages:172 | $ 4485

Iliac Stents Market By Type & Product Technology (Self-Expandable Stents, Balloon-Expandable Stents, Covered Stents (Stent Grafts)); By Anatomical Application & Lesion Type (Common Iliac Artery Lesions, External Iliac Artery Lesions, Severe Calcified / Complete Obstructive Lesions, May-Thurner Syndrome, Deep Vein Thrombosis (DVT) / Post-Thrombotic Syndrome); By Device Material (Nickel-Titanium (Nitinol), Cobalt-Chromium & Stainless Steel); By Clinical Indication (De Novo Iliac Disease, Restenotic Iliac Disease, Iliac Aneurysms and Arterial Injuries); By End User (Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Iliac Stents Market, and How Are Vascular Disease Prevalence and Advanced Stenting Technologies Driving Its Growth?

The Global Iliac Stents Market was valued at USD 903.8 million in 2025 and is projected to reach USD 1.46 billion by 2032, growing at a CAGR... Read More
Published Date: Oct-2026 | No Of Pages:161 | $ 4485

Paget’s Disease Treatment Market By Drug Class (Bisphosphonates [Nitrogen-Containing Bisphosphonates, Non-Nitrogen Bisphosphonates], Calcitonin Analogues [Salmon Calcitonin, Human Calcitonin], Analgesics & NSAIDs [Acetaminophen, Ibuprofen, Other Anti-Inflammatory Medications], Nutritional Supplements [Calcium, Vitamin D]); By Specific Drug / Brand Formulations (Zoledronic Acid [Reclast and Other Zoledronic Acid Formulations], Risedronate Sodium [Actonel and Generic Formulations], Alendronate [Fosamax and Generic Formulations], Pamidronate [Aredia], Other Formulations); By Route of Administration (Intravenous (IV) Administration, Oral Administration, Nasal and Other Non-Oral Supportive Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies & Drug Stores); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Global Paget’s Disease Treatment Market Expanding Through Advanced Bisphosphonate Therapies and Improved Bone Disease Management?

The Global Paget’s Disease Treatment Market was valued at an estimated USD 109.58 million in 2025 and is projected ... Read More
Published Date: OCT-2026 | No Of Pages:151 | $ 4485

Hemarthrosis Treatment Market By Condition / Etiology Type (Hemophilia A Hemarthrosis, Hemophilia B Hemarthrosis, Other Coagulopathies & Rare Bleeding Disorders, Ligamentous & Meniscal Injury-Related Hemarthrosis, Intra-Articular Fracture-Related Hemarthrosis, Postoperative Hemarthrosis (Joint Replacement Complications)); By Treatment & Therapy Type (Plasma-Derived Factor Concentrates, Recombinant Factor Concentrates, Adjunctive Pharmacological Agents, Novel & Emerging Biologics, Joint Aspiration (Arthrocentesis), Geniculate Artery Embolization (GAE), Surgical Synovectomy, Conservative Management (RICE and Supportive Care)); By Management Strategy / Regimen (Prophylaxis Therapy, On-Demand (Episodic) Therapy); By Distribution Channel (Hospital Pharmacies & Inpatient Centers, Specialty Pharmacies & Hemophilia Treatment Centers (HTCs)); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Rising Hemophilia Cases, Recurrent Joint Bleeding, and Advanced Treatment Technologies Shaping the Hemarthrosis Treatment Market?

The Global Hemarthrosis Treatment Market was estimated at USD 1.11 billion in 2025 and projected to reach USD 1.49 billion by 2032... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

Aquaculture Bacterial Treatment Market By Treatment Type (Antibiotics, Probiotics, Bacterial Vaccines, Bacteriophage Therapy, Immunostimulants); By Bacterial Disease (Vibriosis, Aeromonas Infections, Streptococcosis, Columnaris Disease, Edwardsiellosis); By Species (Finfish, Crustaceans, Mollusks); By Route of Administration (Oral Administration, Injectable Administration, Immersion Administration, Water-Based Administration); By Application (Disease Treatment, Disease Prevention, Bacterial Infection Control); By End User (Commercial Fish Farms, Shrimp Farms, Hatcheries, Nurseries); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Disease Prevention and Therapeutic Advancements Shaping the Aquaculture Bacterial Treatment Market?

The Global Aquaculture Bacterial Treatment Market was estimated at USD 1.65 billion in 2025 and is projected to reach USD 2.74 billion by 2032, registering a CA... Read More
Published Date: OCT-2026 | No Of Pages:151 | $ 4485

GNE Myopathy Treatment Market By Treatment Type (Supportive and Symptomatic Care, Disease-Modifying Therapy); By Drug Class (Sialic Acid Replacement, ManNAc, Gene Therapy); By Route of Administration (Oral, Injectable/Intravenous); By End User (Hospitals, Specialized Neuromuscular Clinics, Rehabilitation Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

GNE Myopathy Treatment Market: How Are Disease Prevalence, Therapeutic Advancements, and Emerging Treatments Shaping the Treatment Landscape?

The Global GNE Myopathy Treatment Market was estimated at USD 11.47 million in 2025 and is projected to reach USD 29.05 millio... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

U.S. Perimenopausal & Menopausal Female Sexual Health Therapeutics Market By Therapeutic Segment (GSM/VVA Therapeutics, Dyspareunia-Driven Therapeutics, HSDD Therapeutics, Emerging Arousal & Sexual Function Therapies); By Clinical Condition (Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Dyspareunia, Hypoactive Sexual Desire Disorder, Female Sexual Interest/Arousal Disorder, Female Sexual Arousal Dysfunction, Vasomotor Symptoms with GSM); By Menopausal Stage (Perimenopause [Early & Late Transition], Postmenopause [Early, Established & Late]); By Treatment Type (Vaginal Estrogen, Vaginal DHEA/Prasterone, Selective Estrogen Receptor Modulators, Systemic Menopausal Hormone Therapy, HSDD Pharmacotherapy, Emerging Targeted Therapies); By Route of Administration (Vaginal Creams, Vaginal Tablets & Inserts, Vaginal Rings, Oral Therapy, Transdermal Therapy, Injectable Therapy); By Patient Population (GSM/VVA Patients, Dyspareunia Patients, HSDD Patients, Overlapping GSM & Sexual Dysfunction Patients); By Treatment Journey (Symptom Recognition, Prescription Initiation, Treatment Switching, Treatment Persistence); By End User (OB/GYN Specialists, Menopause Specialists, Primary-Care Physicians, Urogynecologists & Urologists, Sexual-Medicine Specialists); By Geography (United States), Segment Revenue Estimation, Forecast, 2026–2036

How Are Prescription Uptake and Treatment Innovation Shaping the U.S. Perimenopausal and Menopausal Female Sexual Health Therapeutics Market?

The U.S. Perimenopausal and Menopausal Female Sexual Health Therapeutics Market is estimated at US$1.05 billion in 2026 and is... Read More
Published Date: Oct-2026 | No Of Pages:165 | $ 4485

Krabbe Disease Treatment Market By Treatment Type (Hematopoietic Stem Cell Transplantation [HSCT], Supportive & Symptomatic Care, Gene Therapy); By Disease Type (Infantile Krabbe Disease, Late-Onset Krabbe Disease); By Therapy Approach (Allogeneic Stem Cell Transplantation [Bone Marrow Transplantation, Umbilical Cord Blood Transplantation], Rehabilitation Therapy & Associated Supportive Care [Physical Therapy, Occupational Therapy, Symptom Management], Adeno-Associated Virus [AAV] Gene Therapy); By Age Group (Infants, Children, Adults); By End User (Specialty Hospitals, Pediatric Transplant Centers, Neurology Clinics); By Geography (North America, Europe, Asia-Pacific), Segment Revenue Estimation, Forecast, 2026–2032

Krabbe Disease Treatment Market: How Are Early Diagnosis, Treatment Advancements, and Gene Therapy Transforming Patient Care?

The Global Krabbe Disease Treatment Market was estimated at USD 48.55 million in 2025 and is projected to reach USD 81.90 million by 2032, exp... Read More
Published Date: Oct-2026 | No Of Pages:151 | $ 4485

Necrotizing Autoimmune Myositis Market By Disease Type (Anti-HMGCR Immune-Mediated Necrotizing Myopathy, Anti-SRP Immune-Mediated Necrotizing Myopathy, Seronegative Immune-Mediated Necrotizing Myopathy); By Treatment Type (Intravenous Immunoglobulin [IVIG] Therapy, Immunosuppressive Therapy, Biologic Therapy, Corticosteroid Therapy); By Drug Class (Immunoglobulins, Immunosuppressants [Methotrexate, Mycophenolate, Azathioprine], Monoclonal Antibodies [Rituximab, Emerging Targeted Therapies], Corticosteroids); By Diagnosis (Autoantibody Testing [Anti-HMGCR, Anti-SRP], Creatine Kinase [CK] Testing, Muscle Biopsy, Magnetic Resonance Imaging [MRI], Electromyography [EMG]); By Route of Administration (Intravenous Administration, Oral Administration, Subcutaneous Administration); By End User (Hospitals, Rheumatology Clinics, Infusion Centers, Neurology Clinics); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Rising Diagnosis Rates, Severe Muscle Weakness, and Long-Term Treatment Needs Shaping the Necrotizing Autoimmune Myositis Market?

The Global Necrotizing Autoimmune Myositis Market was estimated at USD 692.0 million in 2025 and is projected to reach USD 1,257.6... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market By Drug Class (Targeted Disease-Modifying Therapies, Non-Steroidal Anti-Inflammatory Drugs [NSAIDs] & COX-2 Inhibitors, Corticosteroids, Bisphosphonates); By Treatment Type (Medication, Occupational & Gentle Physical Therapy, Surgery [Exceptional/Emergency Procedures]); By Route of Administration (Oral Administration, Parenteral/Intravenous Administration, Topical Administration); By End User & Distribution Channel (Specialty, Retail & Online Pharmacies, Hospitals & Specialty Clinics); By Geography (North America, Asia-Pacific, Europe, Middle East & Africa, Latin America), Segment Revenue Estimation, Forecast, 2026–2032

How Are New Drug Approvals, Targeted Therapies, and Expanding Treatment Access Driving Growth in the Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market?

The Global Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market was valued at USD 27.8 million in... Read More
Published Date: Oct-2026 | No Of Pages:159 | $ 4485

Venous Reflux Disease Treatment Market By Treatment Type (Endovenous Thermal Ablation [Radiofrequency Ablation (RFA), Endovenous Laser Ablation (EVLA)], Non-Thermal Ablation [Medical Adhesive Closure, Mechanochemical Ablation], Sclerotherapy, Surgical Treatment, Conservative Treatment); By Disease Type (Superficial Venous Reflux, Deep Venous Reflux); By End User (Specialty Vein Clinics, Hospitals, Ambulatory Surgery Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Clinical Applications and Treatment Advancements Shaping the Global Venous Reflux Disease Treatment Market?

The Global Venous Reflux Disease Treatment Market was valued at USD 418 million in 2025 and is projected to reach USD 629 million by 2032, expanding at ... Read More
Published Date: OCT-2026 | No Of Pages:168 | $ 4485

X-Linked Hypophosphatemia (XLH) Market By Therapeutics (Injectable Medications [Biologics], Oral Medications [Conventional Therapies], Emerging & Gene Therapies); By Patient Type (Pediatric Population, Adult Population); By Distribution Channel (Specialty/Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); By End User (Hospitals & Clinics, Homecare Settings, Research & Academic Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Biologic Innovation, Lifelong Treatment Needs, and Expanding Global Access Shaping the X-Linked Hypophosphatemia Market?

The Global X-Linked Hypophosphatemia Market was estimated at USD 1.56 billion in 2025 and is projected to reach USD 3.00 billion by 2032, e... Read More
Published Date: Oct-2026 | No Of Pages:161 | $ 4485

Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market By Treatment Type (Implantable Cardioverter Defibrillators [ICDs], Medication, Catheter Ablation, Heart Transplantation); By Drug Class (Beta-Blockers, Antiarrhythmic Drugs, ACE Inhibitors & ARBs, Diuretics, Other Supportive Medications); By Diagnostic Method (Electrocardiography [ECG], Cardiac Magnetic Resonance Imaging [MRI], Genetic Testing, Echocardiography, Holter & Ambulatory ECG Monitoring, Electrophysiological Studies); By Device Type (Transvenous Implantable Cardioverter Defibrillators, Subcutaneous Implantable Cardioverter Defibrillators, Cardiac Monitoring Devices); By End User (Hospitals, Specialty Cardiology Clinics, Diagnostic Centers, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Are Genetic Screening, Implantable Defibrillators, and Emerging Gene Therapies Reshaping the Arrhythmogenic Right Ventricular Dysplasia Market?

The Global Arrhythmogenic Right Ventricular Dysplasia (ARVD) Market was valued at USD 1.05 billion in 2025 and is projec... Read More
Published Date: Oct-2026 | No Of Pages:169 | $ 4485

APOL1-Mediated Kidney Disease Treatment Market By Treatment Type (Supportive & Standard Care, APOL1 Small-Molecule Inhibitors, Pathway & Inflammatory Modulators, Antisense Oligonucleotides & Gene-Silencing Therapies); By Disease Indication (Focal Segmental Glomerulosclerosis [FSGS], Hypertensive-Attributed Chronic & End-Stage Kidney Disease, HIV-Associated Nephropathy [HIVAN], Lupus Nephritis-Related & Other Proteinuric Kidney Disorders); By Genetic Testing & Diagnostic Method (Biomarker & Proteinuria Profiling, APOL1 Genotyping Assays); By End User (Hospitals, Specialized Nephrology Clinics & Centers, Specialty & Online Pharmacies); By Geography (North America, Europe, Latin America, Middle East & Africa, Asia-Pacific), Segment Revenue Estimation, Forecast, 2026–2032

How Are Genetically Targeted Therapies Reshaping the APOL1-Mediated Kidney Disease Treatment Market?

The Global APOL1-Mediated Kidney Disease Treatment Market was valued at USD 1.34 billion in 2025 and is projected to reach USD 4.72 billion by 2032, expanding at a CAG... Read More
Published Date: Oct-2026 | No Of Pages:157 | $ 4485

FcRn Inhibitors Market By Drug (Efgartigimod, Rozanolixizumab, Nipocalimab, Batoclimab & Late-Stage Candidates, Other FcRn Inhibitors); By Indication (Generalized Myasthenia Gravis [gMG], Chronic Inflammatory Demyelinating Polyneuropathy [CIDP], Immune Thrombocytopenia [ITP], Pemphigus, Warm Autoimmune Hemolytic Anemia [wAIHA], Other Autoimmune Diseases); By Route of Administration (Subcutaneous Administration, Intravenous Administration); By End User (Hospitals, Specialty Clinics, Infusion Centers, Home Care); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are New Indications and Subcutaneous Therapies Accelerating the FcRn Inhibitors Market?

The Global FcRn Inhibitors Market was valued at USD 4.58 billion in 2025 and is projected to reach USD 13.34 billion by 2032, expanding at a CAGR of 16.5% during 2026–203... Read More
Published Date: OCT-2026 | No Of Pages:165 | $ 4485

Small Intestinal Bacterial Overgrowth Treatment Market By Therapy Type (Antibiotic Therapy [Rifaximin, Neomycin, Metronidazole, Other Antibiotics], Dietary Interventions [Low-FODMAP Diet, Low-Fermentation Diet, Elemental Diet], Prokinetics & Adjunctive Therapies, Herbal & Natural Antimicrobials [Berberine, Oregano-Derived Formulations, Neem, Allicin-Based Products]); By Indication/Underlying Condition (IBS-Associated SIBO, Motility Disorder-Associated SIBO, Anatomical & Structural Alteration-Associated SIBO, Medication-Induced SIBO, Other Comorbid Disease-Associated SIBO [Celiac Disease, Liver Disease, Inflammatory Bowel Disease]); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are Rifaximin Therapy and Recurrence Management Shaping the Small Intestinal Bacterial Overgrowth Treatment Market?

The Global Small Intestinal Bacterial Overgrowth Treatment Market was valued at USD 548 million in 2025 and is projected to reach USD 835 million by... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

Brugada Syndrome Treatment Market By Treatment Type (Implantable Cardioverter-Defibrillators [ICDs], Epicardial Radiofrequency Ablation, Antiarrhythmic Drug Therapy [Quinidine and Related Pharmacological Management], Emergency & Supportive Rhythm Management [Isoproterenol-Based Treatment and Cardiac Monitoring]); By Diagnosis Method (Electrocardiography & Provocative Drug Testing, Electrophysiological Testing & Mapping, Genetic Testing); By End User (Hospitals, Specialty Cardiac & Electrophysiology Centers, Ambulatory & Specialized Outpatient Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are ICD Protection and Advanced Ablation Reshaping the Brugada Syndrome Treatment Market?

The Global Brugada Syndrome Treatment Market was valued at USD 268 million in 2025 and is projected to reach USD 436 million by 2032, expanding at a CAGR of 7.2% during 2026&... Read More
Published Date: Oct-2026 | No Of Pages:160 | $ 4485

Eosinophilic Pneumonia Treatment Market By Disease Classification (Chronic Eosinophilic Pneumonia [CEP], Acute Eosinophilic Pneumonia [AEP]); By Drug Class (Corticosteroids, Biologic Therapies/Monoclonal Antibodies, Immunosuppressants & Other Supportive Therapies); By Route of Administration (Oral Administration, Parenteral Administration); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Online Pharmacies); By End User (Hospitals & Specialty Clinics, Home Healthcare); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are Steroid-Sparing Biologics and Relapse Care Redefining the Eosinophilic Pneumonia Treatment Market?

The Global Eosinophilic Pneumonia Treatment Market was valued at USD 1.16 billion in 2025 and is projected to reach USD 1.86 billion by 2032, expanding at a CAGR... Read More
Published Date: Oct-2026 | No Of Pages:168 | $ 4485

Marginal Zone Lymphoma Treatment Market By Treatment Type (Immunotherapy & Targeted Therapies, Chemotherapy, Radiation Therapy, Surgery); By Disease Subtype (Extranodal Marginal Zone Lymphoma [MALT Lymphoma], Splenic Marginal Zone Lymphoma [SMZL], Nodal Marginal Zone Lymphoma [NMZL]); By Line of Therapy (First-Line Therapy, Relapsed or Refractory Therapy); By End User (Hospitals, Specialty Cancer & Hematology Centers, Ambulatory Clinics and Other Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Marginal Zone Lymphoma Treatment Market: Targeted Therapies and Cellular Innovation Expand Care

The Global Marginal Zone Lymphoma Treatment Market was valued at USD 2.26 billion in 2025 and is projected to reach USD 3.61 billion by 2032, growing at a CAGR of 6.95% dur... Read More
Published Date: Oct-2026 | No Of Pages:158 | $ 4485

Plantar Fasciitis Treatment Market By Treatment/Product Type (Orthotics, Medication Therapy, Shockwave Therapy, Physical Therapy & Supportive Devices, Surgery and Other Treatments); By Disease/Indication Type (Chronic Plantar Fasciitis, Acute Plantar Fasciitis); By Drug Class (Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Corticosteroids, Other Pharmacological & Injectable Therapies); By End User (Hospitals & Clinics, Home Care/OTC Retail, Ambulatory Surgical Centers [ASCs]); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Plantar Fasciitis Treatment Market: Conservative Care Opens the Door to Advanced Heel Pain Relief

The Global Plantar Fasciitis Treatment Market was valued at USD 1.60 billion in 2025 and is projected to reach USD 2.98 billion by 2032, growing at a CAGR of 9.30% during... Read More
Published Date: OCT-2026 | No Of Pages:161 | $ 4485

Antibiotic Infusion Therapy Market By Antibiotic Class (Cephalosporins, Penicillins, Carbapenems, Glycopeptides, Aminoglycosides, Lipopeptides, Other Antibiotics); By Infection Type (Complicated Urinary Tract Infections [cUTIs], Respiratory Infections, Skin & Soft Tissue Infections, Bloodstream Infections, Bone & Joint Infections, Intra-abdominal Infections, Endocarditis, Others); By Route of Administration (Intravenous [IV], Intramuscular [IM], Other Routes); By Delivery Method (Intermittent Infusion, Continuous Infusion, IV Push); By Vascular Access (Peripheral IV Cannulas, Peripherally Inserted Central Catheters [PICCs], Central Venous Catheters, Implanted Ports); By Treatment Setting (Hospitals, Outpatient Infusion Centers, Home Healthcare, Skilled Nursing Facilities); By Patient Type (Adults, Geriatric Patients, Pediatric Patients); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Home Infusion Providers, Retail Pharmacies, Other Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Antibiotic Infusion Therapy Market: Hospital-to-Home Care Expands the Treatment Frontier

The Global Antibiotic Infusion Therapy Market was valued at USD 36.87 billion in 2025, projected to reach USD 55.96 billion by 2032, growing at a CAGR of 6.15%, according to Strat... Read More
Published Date: Oct-2026 | No Of Pages:160 | $ 4485

Pyruvate Kinase Deficiency Market By Treatment Type (Targeted Disease-Modifying Therapies, Blood Transfusion and Supportive Care, Iron Overload and Complication Management, Splenectomy and Procedure-Based Management, Stem Cell Transplantation and Other Advanced Therapies); By Diagnosis / Testing (Genetic Testing, Pyruvate Kinase Activity Assays, Complete Blood Count and Blood Smear Testing, Other Biochemical and Hemolysis Tests); By End User (Hospitals & Specialty Clinics, Rare Blood Disorder & Hematology Centers, Research Institutes, Home Healthcare Services); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Pyruvate Kinase Deficiency Market: Targeted Therapies Transform Lifelong Care

The Global Pyruvate Kinase Deficiency Market was valued at USD 1.12 billion in 2025 and is projected to reach USD 2.03 billion by 2032, expanding at a CAGR of 8.96% during 2026–2032.Read More
Published Date: Oct-2026 | No Of Pages:161 | $ 4485

Toxoplasmosis Treatment Market By Disease Type (Acquired Toxoplasmosis [Acute Acquired Toxoplasmosis, Chronic/Latent Acquired Toxoplasmosis], Congenital Toxoplasmosis [Ocular Toxoplasmosis, Intracranial Manifestations, Systemic Neonatal Infection]); By Drug Class (Pyrimethamine, Sulfadiazine, Spiramycin, Leucovorin/Folic Acid, Alternative and Other Agents [Clindamycin, Atovaquone, Azithromycin, Trimethoprim-Sulfamethoxazole]); By Route of Administration (Oral Administration [Tablets, Capsules], Parenteral Administration [Intravenous, Intramuscular]); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Providers/E-commerce Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Toxoplasmosis Treatment Market: Congenital and Ocular Care Sustain Therapeutic Demand

The Global Toxoplasmosis Treatment Market was valued at USD 675.47 million in 2025 and is projected to reach USD 922.30 million by 2032, expanding at a CAGR of 4.55% during 2026&ndas... Read More
Published Date: Oct-2026 | No Of Pages:151 | $ 4485

Gaucher Disease Treatment Market By Therapy Type (Enzyme Replacement Therapy [ERT], Substrate Reduction Therapy [SRT], Emerging Therapies and Supportive Treatments); By Disease Type (Type 1 Gaucher Disease [Non-Neuronopathic], Type 2 Gaucher Disease [Acute Neuronopathic], Type 3 Gaucher Disease [Chronic Neuronopathic]); By Route of Administration (Intravenous [IV] Administration, Oral Administration); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online and Retail Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Gaucher Disease Treatment Market: Advancing Rare Disease Management Through Lifelong Enzyme Replacement, Oral Therapies, and Precision Treatment Approaches

The Global Gaucher Disease Treatment Market was valued at USD 1.68 billion in 2025 and is projected to reach USD... Read More
Published Date: Oct-2026 | No Of Pages:162 | $ 4485

Hedgehog Pathway Inhibitors Market By Drug Type (Vismodegib [Erivedge], Sonidegib [Odomzo], Glasdegib [Daurismo], Next-Generation and Investigational Hedgehog Inhibitors); By Disease Indication (Basal Cell Carcinoma [BCC], Acute Myeloid Leukemia [AML], Other Oncology and Rare Indications); By Route of Administration & Dosage Form (Oral Capsules, Oral Tablets, Parenteral and Topical Formulations); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail and Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Hedgehog Pathway Inhibitors Market: Blocking Tumor Signals, Opening New Oncology Pathways

The Global Hedgehog Pathway Inhibitors Market was valued at USD 642.19 million in 2025 and is projected to reach USD 1.37 billion by 2032, expanding at a CAGR of 11.40% during 20... Read More
Published Date: Sep-2026 | No Of Pages:156 | $ 4485

NTRK Fusion Cancer Treatment Market By Product Type (Therapeutics, Diagnostics); By Tumor Origin (Lung Cancer, Colorectal Cancer, Thyroid Cancer, Salivary Gland Cancer, Other Solid Tumors including Infantile Fibrosarcoma, Pediatric Gliomas and Secretory Breast Carcinoma); By End User (Hospitals and Clinics, Cancer Centers and Specialized Oncology Institutions, Diagnostic Laboratories); By Geography (North America, Europe, Asia-Pacific, Rest of the World), Segment Revenue Estimation, Forecast, 2026–2032

NTRK Fusion Care Grows with Molecular Testing Reach

The Global NTRK Fusion Cancer Treatment Market was valued at USD 350.95 million in 2025 and is projected to reach USD 614.20 million by 2032, expanding at a CAGR of 8.3% during 2026–2032, according to Strategic... Read More
Published Date: Sep-2026 | No Of Pages:151 | $ 4485

Desmoid Tumor Treatment Market By Treatment Type (Targeted Therapy, Active Surveillance and Minimally Invasive Procedures, Surgery, Chemotherapy and Other Systemic Treatments); By Diagnosis Type (Biopsy-Based Diagnosis, Immunohistochemical Analysis, Electron Microscopic Examination and Other Diagnostic Methods); By End User (Hospitals and Multispecialty Healthcare Systems, Specialty Sarcoma and Oncology Centers, Ambulatory and Outpatient Treatment Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Targeted Drugs Open a New Growth Phase in Desmoid Tumor Care

The Global Desmoid Tumor Treatment Market was valued at USD 350 million in 2025 and is projected to reach USD 890 million by 2032, expanding at a CAGR of 14.25% during 2026–2032.

... Read More
Published Date: SEP-2026 | No Of Pages:162 | $ 4485

Ovarian Cancer Therapeutics Market By Drug Class (PARP Inhibitors, Platinum-Based Chemotherapy, Taxanes, VEGF/Anti-Angiogenic Agents, Antibody-Drug Conjugates, Immunotherapies, Other Drug Classes); By Therapy Type (Targeted Therapy, Chemotherapy, Immunotherapy, Hormone Therapy, Other Therapies and Combination Regimens); By Disease Indication (Epithelial Ovarian Cancer, Fallopian Tube and Primary Peritoneal Cancer, Rare Ovarian Tumors); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail and Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ovarian Cancer Therapeutics Market Shifts Toward Biomarker-Led Treatment

The Global Ovarian Cancer Therapeutics Market was valued at USD 4.12 billion in 2025 and is projected to reach USD 6.43 billion by 2032, expanding at a CAGR of 6.57% during 2026–2032, accor... Read More
Published Date: Sep-2026 | No Of Pages:172 | $ 4485

Gastric Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Supportive Care); By Drug Class (Cytotoxic Agents, HER2-Targeted Therapies and Antibody-Drug Conjugates, PD-1/PD-L1 Immune Checkpoint Inhibitors, VEGF, FGFR2, Claudin 18.2 and Other Targeted Agents); By Disease Indication (Gastric Adenocarcinoma and Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumors, Gastric Neuroendocrine Tumors and Other Rare Gastric Tumors); By Route of Administration (Intravenous Therapies, Oral Therapies); By End User (Hospitals and Comprehensive Cancer Centers, Specialty Oncology Clinics, Research Institutes and Other Healthcare Facilities); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Where Is the Gastric Cancer Therapeutics Market Headed as Biomarker-Based Care Expands?

The Global Gastric Cancer Therapeutics Market was valued at USD 5.15 billion in 2025 and is projected to reach USD 10.56 billion by 2032, expanding at a CAGR of 10.85% during 2026&... Read More
Published Date: Sep-2026 | No Of Pages:168 | $ 4485

Gallbladder Cancer Treatment Market By Therapy Type (Chemotherapy, Immunotherapy, Surgical Intervention, Targeted Therapy, Radiation Therapy); By Disease Stage (Early-Stage & Localized Gallbladder Cancer, Advanced, Metastatic & Unresectable Gallbladder Cancer); By Route of Administration (Parenteral/Intravenous Administration, Oral Administration); By End User (Hospitals & Associated Oncology Centers, Specialty Cancer & Hepatobiliary Centers, Academic & Medical Research Institutes, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Gallbladder Cancer Treatment Market: Precision Therapies Gain Ground as Late Diagnosis Sustains Systemic Demand

The Global Gallbladder Cancer Treatment Market was valued at USD 280 million in 2025 and is projected to reach USD 460 million by 2032, expanding at a CAGR ... Read More
Published Date: SEP-2026 | No Of Pages:169 | $ 4485

Acute Ischemic Stroke Market By Drug Class (Thrombolytics, Antiplatelets, Anticoagulants, Other Drug Therapies); By Application (Acute Reperfusion, Early Recurrence Prevention, Supportive Medical Management); By Treatment Approach (Intravenous Thrombolysis, Mechanical Thrombectomy, Neuroprotective Therapy); By End User (Hospitals & Stroke Centers, Specialty Clinics, Academic & Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Acute Ischemic Stroke Market: The Reperfusion Race Accelerates Treatment Demand

The Global Acute Ischemic Stroke Market was valued at USD 4.05 billion in 2025 and is projected to reach USD 6.75 billion by 2032, expanding at a CAGR of 7.85% during 2026–2032, acco... Read More
Published Date: Sep-2026 | No Of Pages:168 | $ 4485

Zellweger Syndrome Treatment Market By Disease Type (Zellweger Syndrome, Infantile Refsum Disease, Neonatal Adrenoleukodystrophy, Heimler Syndrome); By Treatment Approach (Supportive Care, Nutritional Management, Seizure Management, Liver-Related Treatment, Vitamin Supplementation, Genetic Counseling); By Diagnostic Method (Genetic Testing, VLCFA Analysis, Biochemical Testing, Metabolic Profiling, Imaging-Based Assessment); By Healthcare Provider (Pediatricians, Neurologists, Genetic Specialists, Gastroenterologists, Hepatologists, Other Specialists); By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Genetic Testing Laboratories, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Zellweger Syndrome Treatment Market: Supportive Care Leads as Genetic Testing Expands Earlier Diagnosis

The Global Zellweger Syndrome Treatment Market was valued at USD 65 million in 2025 and is projected to reach USD 115 million by 2032, expanding at a CAGR of 8.50% ... Read More
Published Date: SEP-2026 | No Of Pages:156 | $ 4485

Hypoactive Sexual Desire Disorder (HSDD) Treatment Market By Therapy Type (Non-Hormonal Agents, Hormonal Therapies, Off-Label Pharmacological Therapies, Psychological and Behavioral Therapies); By Drug Class (Flibanserin, Bremelanotide, Testosterone-Based Therapies, Other Targeted Therapies); By Route of Administration (Oral Therapies, Injectable Therapies, Topical and Transdermal Therapies); By Distribution Channel (Retail Pharmacies, Online and Mail-Order Pharmacies, Hospital Pharmacies); By End User (Hospitals, Specialty Women’s Health Clinics, Telehealth Platforms, Other Healthcare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

HSDD Treatment Market: Non-Hormonal Therapies and Digital Access Expand Women’s Sexual Health Care

The Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market was valued at USD 725 million in 2025 and is projected to reach USD 1.17 billion by 2032, expa... Read More
Published Date: Sep-2026 | No Of Pages:168 | $ 4485

Eosinophilic Granulomatosis with Polyangiitis Treatment Market By Drug Class (Biologic Therapies, Steroids/Glucocorticoids, Immunosuppressants, Immune Globulins and Other Adjunctive Therapies); By Route of Administration (Subcutaneous/Intramuscular, Oral, Intravenous); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail and Online Pharmacies); By End User (Hospitals and Clinics, Home Healthcare); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Eosinophilic Granulomatosis with Polyangiitis Treatment Market: Biologics Redefine Steroid-Sparing Disease Control

The Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market was valued at USD 415 million in 2025 and is projected to reach USD 810 million... Read More
Published Date: SEP-2026 | No Of Pages:169 | $ 4485

Wiskott-Aldrich Syndrome Treatment Market By Treatment Type (Hematopoietic Stem-Cell Transplantation, Immunoglobulin Replacement Therapy, Supportive and Symptomatic Care, Antibiotic and Antimicrobial Therapy, Gene Therapy); By Diagnosis Method (Genetic Testing, Blood Tests, Flow Cytometry and Other Diagnostic Procedures); By Distribution Channel (Hospital Pharmacies, Specialty and Institutional Distribution, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Transplant Centers, Specialty Immunology and Hematology Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Wiskott-Aldrich Syndrome Treatment Market: Curative Transplants and Gene Therapy Redefine Rare-Disease Care

The Global Wiskott-Aldrich Syndrome Treatment Market was valued at USD 275 million in 2025 and is projected to reach USD 630 million by 2032, expanding at a CAG... Read More
Published Date: Sep-2026 | No Of Pages:165 | $ 4485

Dyspnea Treatment Market By Treatment Type (Supplemental Oxygen and Ventilatory Therapy, Pharmacological Therapy, Non-Pharmacological and Behavioral Therapy); By Route of Administration (Inhalation, Oral Administration, Intravenous and Other Parenteral Administration); By End User (Hospitals and Emergency Departments, Home-Care Settings, Outpatient and Rehabilitation Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Dyspnea Treatment Market Overview: Cause-Specific Care Expands Across Acute, Chronic, and Home Settings

The Global Dyspnea Treatment Market was valued at USD 6.35 billion in 2025 and is projected to reach USD 9.60 billion by 2032, expanding at a CAGR of 6.25% during 2... Read More
Published Date: SEP-2026 | No Of Pages:167 | $ 4485

Tissue Kallikrein 1 (KLK1) Therapeutics Market By Product Type (Native/Urinary KLK1, Recombinant KLK1); By Indication (Acute Ischemic Stroke, Preeclampsia, Chronic Kidney Disease, Hypertension, Other Applications); By Mechanism (Vasodilation and Endothelial Function, Anti-inflammatory and Tissue-Protective Activity); By Route of Administration (Injectable KLK1 Therapeutics, Advanced and Targeted Delivery Approaches); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Research and Clinical-Trial Supply Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

KLK1 Therapeutics Move from Regional Stroke Use toward Recombinant Vascular Restoration

The Global Tissue Kallikrein 1 (KLK1) Therapeutics Market was valued at USD 420 million in 2025 and is projected to reach USD 1.37 billion by 2032... Read More
Published Date: SEP-2026 | No Of Pages:152 | $ 4485

Hypercholesterolemia Drugs Market By Drug Class (Statins, PCSK9 Inhibitors, PCSK9-Targeting siRNA Therapies, Cholesterol Absorption Inhibitors, ATP Citrate Lyase Inhibitors, Bile Acid Sequestrants & Other Relevant Therapies); By Patient Indication (Non-Familial Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Other Hypercholesterolemia); By Prevention Setting (Primary Prevention, Secondary Prevention); By Route of Administration (Oral Formulations, Parenteral Formulations); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online/Mail-Order Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hypercholesterolemia Treatment Expands Across Cardiovascular Prevention

The Global Hypercholesterolemia Drugs Market was valued at USD 16.8 billion in 2025 and is projected to reach USD 26.25 billion by 2032, expanding at a CAGR of 6.85% during 2026–2032, accord... Read More
Published Date: SEP-2026 | No Of Pages:168 | $ 4485

BCMA Targeted Therapies Market By Product Type (CAR-T Cell Therapies, Bispecific Antibodies and T-Cell Engagers, Antibody-Drug Conjugates); By Treatment Application (Late-Line Relapsed or Refractory Multiple Myeloma, Earlier-Line Relapsed Multiple Myeloma); By End User (Hospitals and Academic Medical Centers, Specialty Oncology and Hematology Clinics, Ambulatory and Outpatient Treatment Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

BCMA Therapies Expand the Treatment Window in Multiple Myeloma

The Global BCMA Targeted Therapies Market was valued at USD 9.10 billion in 2025 and is projected to reach USD 23.90 billion by 2032, expanding at a CAGR of 14.85% during 2026–2032, according to Stra... Read More
Published Date: Sep-2026 | No Of Pages:176 | $ 4485

Schwannomatosis Therapeutics Market By Drug Class (Anti-Angiogenic & VEGF Agents, Other Targeted Kinase Inhibitors, Gabapentinoids & Ion-Channel Modulators, Antidepressants & Other Pain Medicines, MEK & mTOR Inhibitors); By Route of Administration (Oral Administration, Injectable & Intravenous Administration); By Distribution Channel (Hospital Pharmacies, Specialty & Retail Pharmacies, Online/Digital Pharmacies); By End User Setting (Hospitals & Advanced Surgical Centers, Specialized Neurofibromatosis & Comprehensive Tumor Clinics, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Schwannomatosis Therapeutics Move Toward Subtype-Specific Tumor Control and Functional Preservation

The Global Schwannomatosis Therapeutics Market was valued at USD 175 million in 2025 and is projected to reach USD 325 million by 2032, expanding at a CAGR of 9.25% dur... Read More
Published Date: SEP-2026 | No Of Pages:172 | $ 4485

Semaglutide Market By Product Type (Ozempic, Wegovy, Rybelsus); By Indication (Type 2 Diabetes Management, Chronic Weight Management, Cardiovascular Risk Reduction, Other Emerging Indications); By Route of Administration (Injectable Semaglutide, Oral Semaglutide); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); By End User (Homecare Settings, Hospitals and Clinics, Specialty Diabetes and Obesity Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Semaglutide Expands Across Metabolic Care as Safety Monitoring Intensifies

The Global Semaglutide Market was valued at USD 29.5 billion in 2025 and is projected to reach USD 65.1 billion by 2032, expanding at a CAGR of 12.25% during 2026–2032, according to Strat... Read More
Published Date: SEP-2026 | No Of Pages:169 | $ 4485

Herpes Zoster Treatment Market By Treatment Type (Antiviral Medications, Analgesics and Pain-Management Therapy, Anti-Inflammatory Medications, Other Supportive Treatments); By Route of Administration (Oral, Injectable, Topical); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Care Centers, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Herpes Zoster Treatment Market Shifts From Acute Viral Control to Long-Term Complication Management

The Global Herpes Zoster Treatment Market was valued at USD 620 million in 2025 and is projected to reach USD 866 million by 2032, expanding at a CAGR of 4.85% during 2... Read More
Published Date: Sep-2026 | No Of Pages:176 | $ 4485

Duodenoscope Market By Product Type (Flexible Video Duodenoscopes, Flexible Non-Video Duodenoscopes, Rigid Duodenoscopes, Single-Use Duodenoscopes); By Application (Therapeutic Procedures, Diagnostic Procedures); By Usability (Reusable Duodenoscopes, Disposable Duodenoscopes, Disposable Distal-Cap Duodenoscopes); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Pediatric Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Duodenoscope Market Moves Toward Infection-Safe, Procedure-Ready ERCP Platforms

The Global Duodenoscope Market was valued at USD 360 million in 2025 and is projected to reach USD 550 million by 2032, growing at a CAGR of 6.40% during 2026–2032, according to Stra... Read More
Published Date: Sep-2026 | No Of Pages:168 | $ 4485

Flow Diverters Market By Product Type (Pipeline Flow Diverters, FRED Flow Diverters, Surpass Flow Diverters, Other Flow Diverter Devices); By Application (Intracranial Aneurysm Treatment, Wide-Neck Aneurysm Treatment, Other Neurovascular Applications); By Material (Cobalt-Chromium Alloy Devices, Nitinol-Based Devices); By End User (Hospitals, Specialty Neurovascular Centers, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Surface Engineering and Precision Vessel Reconstruction Reshape the Flow Diverters Market

The Global Flow Diverters Market was valued at USD 560 million in 2025 and is projected to reach USD 980 million by 2032, expanding at a CAGR of 8.40% during 2026–2032, acc... Read More
Published Date: Sep-2026 | No Of Pages:165 | $ 4485

PET-CT Scanner Device Market By Product Type (Stationary PET-CT Scanners, Portable/Mobile PET-CT Scanners); By Detector Type (Full-Ring PET-CT Scanners, Partial-Ring PET-CT Scanners); By Application (Oncology, Cardiology, Neurology, Other Applications); By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutions, Ambulatory Surgical Centers, Other Facilities); By Modality (Hybrid PET-CT Scanners, Standalone PET Scanners, Standalone CT Scanners); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Utilization Growth, Molecular Imaging Expansion, and Theranostics Reshape the PET-CT Scanner Device Market

The Global PET-CT Scanner Device Market was valued at USD 2.80 billion in 2025 and is projected to reach USD 4.37 billion by 2032, expanding at a CAGR of 6.55% d... Read More
Published Date: SEP-2026 | No Of Pages:172 | $ 4485

Adenoid Cystic Carcinoma Treatment Market By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Investigational Therapies); By Disease Stage (Localized Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma); By Route of Administration (Intravenous, Oral, Other Routes); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Cancer Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Precision Oncology and Lifelong Disease Control Reshape the Adenoid Cystic Carcinoma Treatment Market

The Global Adenoid Cystic Carcinoma (ACC) Treatment Market was valued at USD 430 million in 2025 and is projected to reach USD 661 million by 2032, expanding at a CAG... Read More
Published Date: Sep-2026 | No Of Pages:170 | $ 4485

Eosinophilic Esophagitis Treatment Market By Treatment Type (Proton Pump Inhibitors, Corticosteroids, Biologic Therapies, Dietary Therapy, Esophageal Dilation); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Gastroenterology Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Rising Diagnosis and Targeted Immunology Reshape Long-Term EoE Care

The Global Eosinophilic Esophagitis (EoE) Treatment Market was valued at USD 850 million in 2025 and is projected to reach USD 1.98 billion by 2032, expanding at a CAGR of 12.65% during 2026–203... Read More
Published Date: SEP-2026 | No Of Pages:172 | $ 4485

Anorexia Nervosa Treatment Market By Treatment Type (Psychotherapy, Residential and Inpatient Care, Nutritional Counseling, Pharmacotherapy); By Therapy Type (Cognitive Behavioral Therapy, Family Based Treatment, Nutritional Rehabilitation, Medication Management, Interpersonal Therapy); By Age Group (Adolescents, Adults, Children); By End User (Specialized Clinics, Hospitals, Telehealth Providers, Ambulatory Centers); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Integrated Care and Digital Access Are Reshaping Anorexia Nervosa Treatment

The Global Anorexia Nervosa Treatment Market was valued at USD 1.50 billion in 2025 and is projected to reach USD 2.57 billion by 2032, expanding at a CAGR of 7.85% during 2026–2032, acc... Read More
Published Date: SEP-2026 | No Of Pages:148 | $ 4485

Behcet’s Disease Treatment Market By Treatment Type (Biologic Therapies, Immunosuppressants, Corticosteroids, Anti Inflammatory Therapies, Symptomatic Treatments); By Disease Manifestation (Mucocutaneous Behçet’s Disease, Ocular Behçet’s Disease, Vascular Behçet’s Disease, Neuro Behçet’s Disease, Gastrointestinal Behçet’s Disease); By Route of Administration (Injectable, Oral, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Targeted Immunology and Disease-Specific Oral Therapy Advance Behcet’s Disease Care

The Global Behcet’s Disease Treatment Market was valued at USD 590 million in 2025 and is projected to reach USD 960 million by 2032, expanding at a CAGR of 7.25% during 20... Read More
Published Date: SEP-2026 | No Of Pages:168 | $ 4485

Dravet Syndrome Treatment Market By Treatment Type (Antiepileptic Drugs, Cannabidiol Based Therapies, Fenfluramine Based Therapies, Stiripentol Therapy, Gene Targeted Therapies, Adjunctive Therapies); By Therapy Approach (Pharmacological Treatment, Non Pharmacological Treatment); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Specialty Clinics, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Genetic Diagnosis and Syndrome-Specific Therapies Advance Lifelong Dravet Syndrome Management

The Global Dravet Syndrome Treatment Market was valued at USD 470 million in 2025 and is projected to reach USD 937 million by 2032, expanding at a CAGR of 10.25% during 2026... Read More
Published Date: Sep-2026 | No Of Pages:165 | $ 4485

Vulvar Cancer Treatment Market By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy and Supportive Care); By Cancer Stage (Early Stage Vulvar Cancer, Locally Advanced Vulvar Cancer, Metastatic or Recurrent Vulvar Cancer); By Route of Administration (Injectable, Intravenous, Oral, Topical); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Cancer Centers, Specialty Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Vulvar Cancer Treatment Shifts from Surgical Management Toward Biomarker-Guided Oncology

The Global Vulvar Cancer Treatment Market was valued at USD 800 million in 2025 and is projected to reach USD 1.35 billion by 2032, expanding at a CAGR of 7.85% during 2026–... Read More
Published Date: Sep-2026 | No Of Pages:162 | $ 4485

Hand Eczema Treatment Market By Treatment Type (Topical Therapies, Systemic Therapies, Biologic Therapies, Phototherapy, Supportive Skin Barrier Therapies); By Disease Type (Irritant Contact Dermatitis, Allergic Contact Dermatitis, Atopic Hand Eczema, Dyshidrotic Hand Eczema, Hyperkeratotic Hand Eczema); By Route of Administration (Topical Route, Oral Route, Injectable Route); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Dermatology Centers, Specialty Skin Care Clinics, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Targeted Topical Therapies Reshape Chronic Hand Eczema Management

The Global Hand Eczema Treatment Market was valued at USD 75 million in 2025 and is projected to reach USD 131 million by 2032, expanding at a CAGR of 8.25% during 2026–2032, according to Strategi... Read More
Published Date: SEP-2026 | No Of Pages:156 | $ 4485

Cushing Syndrome Treatment Market By Disease Type (Endogenous Cushing Syndrome, Exogenous Cushing Syndrome); By Treatment Type (Drug Therapy, Surgery, Radiation Therapy, Supportive Therapy); By Drug Class (Steroidogenesis Inhibitors, Glucocorticoid Receptor Antagonists, Somatostatin Analogs, ACTH Targeted Therapies); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Endocrine Centers, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cushing Syndrome Treatment Advances Toward Targeted Cortisol Control and Long-Term Disease Management

The Global Cushing Syndrome Treatment Market was valued at USD 970 million in 2025 and is projected to reach USD 1.63 billion by 2032, growing at a CAGR of 7.85% duri... Read More
Published Date: Sep-2026 | No Of Pages:162 | $ 4485

Gonorrhea Market By Treatment Type (Antibiotic Therapy, Combination Therapy, Supportive Treatment); By Drug Class (Cephalosporins, Macrolides, Tetracyclines, Other Antibiotics); By Route of Administration (Injectable, Oral); By Infection Site (Genital Gonorrhea, Rectal Gonorrhea, Pharyngeal Gonorrhea); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Diagnostic Centers, Public Health Organizations); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Gonorrhea Market Advances Through Resistance-Focused Antibiotics and Expanded Diagnostic Access

The Global Gonorrhea Market was valued at USD 2.28 billion in 2025 and is projected to reach USD 3.63 billion by 2032, expanding at a CAGR of 6.87% during 2026–2032, ... Read More
Published Date: Sep-2026 | No Of Pages:162 | $ 4485

Peyronie’s Disease Treatment Market By Therapy Type (Collagenase Injections, Shockwave Therapy, Penile Traction Therapy, Surgery, Other Therapies); By Treatment Type (Drugs, Surgery); By Route of Administration (Oral, Injectable, Topical); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Peyronie’s Disease Treatment Market Advances Through Earlier Diagnosis, Minimally Invasive Care, and Reconstruction

The Global Peyronie’s Disease Treatment Market was valued at USD 0.93 billion in 2025 and is projected to reach USD 1.60 billion by 2032, ex... Read More
Published Date: Sep-2026 | No Of Pages:167 | $ 4485

Von Willebrand Disease Treatment Market By Disease Type (Type 1, Type 2, Type 3, Acquired Von Willebrand Disease); By Treatment Type (Desmopressin, Von Willebrand Factor Replacement Therapy, Antifibrinolytics, Adjunctive Therapies); By Route of Administration (Oral, Intravenous, Subcutaneous, Nasal); By End User (Hospitals, Hemophilia Treatment Centers, Specialty Clinics, Homecare Settings); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Von Willebrand Disease Treatment Market Expands Through Diagnosis, Prophylaxis, and VWF Replacement

The Global Von Willebrand Disease Treatment Market was valued at USD 0.95 billion in 2025 and is projected to reach USD 1.78 billion by 2032, expanding at a CAGR of 9.3... Read More
Published Date: SEP-2026 | No Of Pages:175 | $ 4485

Hidradenitis Suppurativa Treatment Market By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3); By Treatment Type (Medication, Biologics, Antibiotics, Hormonal Therapy, Immune-Suppressive Drugs, Pain Medications, Surgery); By Route of Administration (Oral, Topical, Injectable); By End User (Hospitals, Specialty Clinics, Homecare); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hidradenitis Suppurativa Treatment Market Expansion Through Targeted Biologics and Earlier Disease Control

The Global Hidradenitis Suppurativa Treatment Market was valued at USD 1.46 billion in 2025 and is projected to reach USD 2.97 billion by 2032, expanding at a CA... Read More
Published Date: SEP-2026 | No Of Pages:169 | $ 4485

Conjunctivitis Treatment Market By Drug Class (Antibiotics, Anti-Allergic Treatments, Artificial Tears, Antiviral Therapies, Other Therapies); By Disease Type (Bacterial Conjunctivitis, Allergic Conjunctivitis, Viral Conjunctivitis, Other Types); By Route of Administration (Topical Administration, Oral Administration); By Formulation Type (Eye Drops, Ointments, Tablets and Capsules, Other Formulations); By Distribution Channel (Retail Pharmacies and Drug Stores, Hospital Pharmacies, Online Pharmacies); By End User (Hospitals, Ophthalmology Clinics, Homecare Settings, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Conjunctivitis Treatment Market Growth Shaped by Etiology, Access, and Stewardship

The Global Conjunctivitis Treatment Market was valued at USD 4.08 billion in 2025 and is projected to reach USD 6.14 billion by 2032, expanding at a CAGR of 6.01% during 2026–2032... Read More
Published Date: Sep-2026 | No Of Pages:172 | $ 4485

Comparator Drug Sourcing Market By Drug Type (Reference Drugs, Generic Comparator Drugs, Biosimilar Comparator Drugs, Investigational Comparator Drugs); By Sourcing Model (Direct Manufacturer Sourcing, Authorized Distributor Sourcing, Specialty Procurement Services); By Therapeutic Area (Oncology, Immunology, Cardiovascular Diseases, Neurology, Infectious Diseases, Other Therapeutic Areas); By End User (Pharmaceutical Companies, Contract Research Organizations, Clinical Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Trial Complexity and Global Supply Risk Are Expanding Comparator-Drug Demand

The Global Comparator Drug Sourcing Market was valued at USD 1.51 billion in 2025 and is projected to reach USD 2.38 billion by 2032, expanding at a CAGR of 6.85% during 2026–2032, acco... Read More
Published Date: Sep-2026 | No Of Pages:161 | $ 4485

Lenalidomide Market By Drug Type (Branded Lenalidomide, Generic Lenalidomide); By Application (Multiple Myeloma, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Other Hematological Disorders); By Route of Administration (Oral Capsules); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals, Specialty Cancer Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Lenalidomide Market and What Is Fueling Its Expansion?

The Global Lenalidomide Market was valued at USD 13.50 billion in 2025 and is projected to reach USD 20.10 billion by 2032, expanding at a CAGR of 5.85% during 2026–2032, according to Strate... Read More
Published Date: Sep-2026 | No Of Pages:167 | $ 4485

Schizoaffective Disorder Treatment Market By Treatment Type (Antipsychotic Medications, Mood Stabilizers, Antidepressants, Psychotherapy and Behavioral Therapy, Electroconvulsive Therapy, Supportive and Rehabilitation Therapies); By Drug Class (Atypical Antipsychotics, Typical Antipsychotics, Lithium and Other Mood Stabilizers, Selective Serotonin Reuptake Inhibitors, Other Psychiatric Medications); By Route of Administration (Oral Administration, Injectable Administration, Intramuscular Administration, Intravenous Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies); By End User (Hospitals, Specialty Mental Health Clinics, Research Institutions, Home Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Schizoaffective Disorder Treatment Market Size and What Is Shaping Its Clinical Landscape?

The Global Schizoaffective Disorder Treatment Market was valued at USD 5.30 billion in 2025 and is projected to reach USD 7.85 billion by 2032, expanding at a CAGR o... Read More
Published Date: Sep-2026 | No Of Pages:162 | $ 4485

Facioscapulohumeral Muscular Dystrophy Market By Treatment Type (Supportive Care, Physical Therapy and Rehabilitation, Pain Management, Respiratory Support, Emerging Gene and Molecular Therapies); By Drug Development Stage (Approved Therapies, Clinical Pipeline Therapies, Investigational Therapies); By Route of Administration (Oral, Injectable, Intravenous); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Neuromuscular Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Facioscapulohumeral Muscular Dystrophy Market Size and How Is the Treatment Landscape Evolving?

The Global Facioscapulohumeral Muscular Dystrophy Market was valued at USD 150 million in 2025 and is projected to reach USD 358 million by 2032, expand... Read More
Published Date: Sep-2026 | No Of Pages:172 | $ 4485

Exocrine Pancreatic Insufficiency Market By Treatment Type (Pancreatic Enzyme Replacement Therapy, Nutritional Supplements, Supportive Care, Emerging Therapies); By Indication (Chronic Pancreatitis, Cystic Fibrosis, Pancreatic Cancer, Other Indications); By Route of Administration (Oral Administration, Enteral Administration, Combination Therapy); By End User (Hospitals, Specialty Clinics, Home Care, Retail and Specialty Pharmacies); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Exocrine Pancreatic Insufficiency Market Size and How Is the Treatment Landscape Evolving?

The Global Exocrine Pancreatic Insufficiency (EPI) Market was valued at USD 3.00 billion in 2025 and is projected to reach USD 4.77 billion by 2032, expandin... Read More
Published Date: Sep-2026 | No Of Pages:165 | $ 4485

Glomerulonephritis Market By Disease Type (IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, Chronic Glomerulonephritis, Acute Glomerulonephritis, Other Glomerular Disorders); By Treatment Type (Immunosuppressive Therapy, Corticosteroids, Biologic Therapies, ACE Inhibitors and ARBs, Supportive Care, Diuretics); By Route of Administration (Oral Administration, Injectable Administration, Intravenous Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Nephrology Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Big Is the Glomerulonephritis Market—and Which Therapies Are Redefining Its Future?

The Global Glomerulonephritis (GN) Market was valued at USD 4.15 billion in 2025 and is projected to reach USD 7.43 billion by 2032, expanding at a CAGR of 8.65% during 2026&... Read More
Published Date: Sep-2026 | No Of Pages:169 | $ 4485

Liver Cirrhosis Treatment Market By Therapy Type (Antiviral Therapy, Alcohol Abstinence Management, Lifestyle and Nutritional Management, Immunosuppressive Therapy, Diuretics and Symptom Management, Liver Transplantation, Other Supportive Treatments); By Disease Cause (Alcohol-Related Cirrhosis, Hepatitis B and C-Related Cirrhosis, Non-Alcoholic Fatty Liver Disease-Related Cirrhosis, Autoimmune Hepatitis-Related Cirrhosis, Other Causes); By Route of Administration (Oral, Injectable, Intravenous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Liver Cirrhosis Treatment Market Outlook: Expanding Disease Burden and the New Era of Clinical Innovation

The Global Liver Cirrhosis Treatment Market was valued at USD 7.46 billion in 2025 and is projected to reach USD 12.44 billion by 2032, expanding at a CAGR of 7.5... Read More
Published Date: Sep-2026 | No Of Pages:171 | $ 4485

Ingestible Sensor Market By Sensor Type (Imaging Sensors, Temperature Sensors, Pressure Sensors, pH Sensors, Gas Sensors, Other Sensors); By Application (Gastrointestinal Monitoring, Drug Delivery Monitoring, Patient Monitoring, Clinical Research); By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Institutes, Other End Users); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Ingestible Sensor Market and What Is Fueling Its Expansion?

The Global Ingestible Sensor Market was valued at USD 1.18 billion in 2025 and is projected to reach USD 2.85 billion by 2032, expanding at a 13.5% CAGR during 2026–2032, according to S... Read More
Published Date: SEP-2026 | No Of Pages:160 | $ 4485

Antisense Oligonucleotide Market By Mechanism of Action (RNase H-Mediated Degradation, Splice Modulation, Translation Blocking, Other Mechanisms); By Therapeutic Area (Neurological and Neuromuscular Disorders, Rare Genetic Disorders, Cardiovascular and Metabolic Disorders, Oncology and Hematology, Infectious Diseases, Ophthalmology); By Route of Administration (Subcutaneous, Intrathecal, Intravenous, Intravitreal, Others); By End User (Hospitals, Specialty Clinics, Biopharmaceutical Companies, Academic and Research Institutes); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Antisense Oligonucleotide Market Size and What Is Shaping Its Therapeutic Landscape?

The Global Antisense Oligonucleotide Market was valued at USD 3.92 billion in 2025 and is projected to reach USD 8.52 billion by 2032, expanding at a CAGR of 11.73% during... Read More
Published Date: SEP-2026 | No Of Pages:158 | $ 4485

Waldenstrom Macroglobulinemia Treatment Market By Treatment Type (BTK Inhibitors, Chemoimmunotherapy, Monoclonal Antibodies & Immunotherapy, Proteasome Inhibitors, BCL-2 Inhibitors, Plasmapheresis, Other & Emerging Therapies); By Line of Therapy (First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy); By Route of Administration (Oral Therapy, Intravenous/Parenteral Therapy); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail & Online Pharmacies); By Healthcare Setting (Academic Cancer Centers, Specialty Hematology & Oncology Clinics, Community & Regional Hospitals); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Present Size of the Waldenstrom Macroglobulinemia Treatment Market and How Is the Therapeutic Landscape Changing?

The Global Waldenstrom Macroglobulinemia Treatment Market was valued at USD 460 million in 2025 and is projected to reach USD 790 million by 2... Read More
Published Date: SEP-2026 | No Of Pages:182 | $ 4485

Lewy Body Dementia Treatment Market By Treatment Modality (Pharmacological Treatment [Cholinesterase Inhibitors {Rivastigmine, Donepezil, Galantamine}, Dopaminergic Agents, NMDA Receptor Antagonists], Non-Pharmacological Treatment [Physical Therapy, Cognitive Therapy, Occupational Therapy, Speech Therapy]); By Route of Administration (Oral, Transdermal, Intravenous); By Treatment Line (First-Line Treatment, Second-Line Treatment, Third-Line Treatment); By End User (Hospitals, Specialty Clinics, Home Care Services); By Distribution Channel (Offline Distribution [Retail Pharmacies, Hospital Pharmacies, Specialty and Clinical-Trial Networks], Online Distribution); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Lewy Body Dementia Treatment Market Size and What Is Shaping Its Clinical Landscape?

The Global Lewy Body Dementia Treatment Market was valued at USD 5.08 billion in 2025 and is projected to reach USD 8.60 billion by 2032,... Read More
Published Date: SEP-2026 | No Of Pages:170 | $ 4485

Cannabis Use Disorder Market By Treatment Type (Non-Pharmacological Treatment, Pharmacological Treatment); By Delivery Channel (Outpatient Clinics, Primary Care, Digital Therapeutics, University Programs); By Patient Demographics – Age Group (18–29 Years, 30–45 Years, 45+ Years); By Patient Demographics – Gender (Male, Female); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Cannabis Use Disorder Market Size and How Is the Treatment Landscape Evolving? – (Updated On: 06-Sep-2026)

The Global Cannabis Use Disorder Market was valued at USD 1.56 billion in 2025 and is projected to reach USD 2.46 billion by... Read More
Published Date: MAR-2026 | No Of Pages:168 | $ 4485

Becker Muscular Dystrophy Market By Therapeutic Class (Corticosteroids & Off-Label Supportive Care, Targeted Small Molecules & Muscle Stabilizers, Cardiac & Palliative Interventions); By Mechanism of Action (Anti-Inflammatory & Steroidal Modifiers, Novel & Regenerative Modalities, HDAC Inhibitors, Fast Skeletal Myosin Inhibitors); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Global Becker Muscular Dystrophy Market Size and How Is the Therapeutic Landscape Evolving?

The Global Becker Muscular Dystrophy Market was valued at USD 231.61 million in 2025 and is projected to reach USD 375.30 million by 2032, expanding at a CAGR of 7.... Read More
Published Date: SEP-2026 | No Of Pages:175 | $ 4485

Cannabis Use Disorder Treatment Market By Treatment Type (Non-Pharmacological Treatment, Pharmacological Treatment); By Delivery Channel (Outpatient Clinics, Primary Care, Digital Therapeutics, University Programs); By Patient Demographics – Age Group (18–29 Years, 30–45 Years, 45+ Years); By Patient Demographics – Gender (Male, Female); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Cannabis Use Disorder Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Cannabis Use Disorder Treatment Market was valued at USD 1.56 billion in 2025 and is projected to reach USD 2.46 billion by 2032, expanding at a CAG... Read More
Published Date: Sep-2026 | No Of Pages:172 | $ 4485

Fragile X Syndrome Treatment Market By Treatment Type (Symptomatic Medications, Behavioral Therapy, Educational Support, Emerging Targeted Therapies); By Drug Class (Stimulants, Antidepressants, Antipsychotics, Anticonvulsants, Targeted Molecular Therapies); By Route of Administration (Oral, Injectable); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals & Clinics, Specialty Neurology Centers, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Fragile X Syndrome Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Fragile X Syndrome Treatment Market was valued at USD 1.27 billion in 2025 and is projected to reach USD 2.02 billion by 2032, expanding at a CAGR of 6... Read More
Published Date: SEP-2026 | No Of Pages:170 | $ 4485

Varicose Ulcer Treatment Market By Treatment Type (Compression Therapy, Advanced Wound Dressings, Medications and Topical Agents, Debridement, Negative Pressure Wound Therapy, Skin Substitutes and Grafts, Endovenous Ablation and Surgical Treatment); By Compression Product Type (Compression Bandages, Compression Hosiery, Compression Wraps); By Wound Dressing Type (Foam Dressings, Hydrocolloid Dressings, Alginate Dressings, Hydrogel Dressings, Antimicrobial Dressings, Other Wound Dressings); By End User (Hospitals, Wound Care Centers, Vascular and Specialty Clinics, Home Healthcare); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Varicose Ulcer Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Varicose Ulcer Treatment Market was valued at USD 3.72 billion in 2025 and is projected to reach USD 5.83 billion by 2032, expanding at a CAGR of 6.64% dur... Read More
Published Date: SEP-2026 | No Of Pages:168 | $ 4485

Zika Virus Treatment Market By Treatment Type (Analgesic and Antipyretic Therapy, Hydration and Supportive Care, Investigational Antiviral Therapy); By Route of Administration (Oral, Intravenous, Other Routes); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Public Health Organizations, Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Zika Virus Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Zika Virus Treatment Market was valued at USD 28.40 million in 2025 and is projected to reach USD 40.44 million by 2032, expanding at a CAGR of 5.18% during 20... Read More
Published Date: SEP-2026 | No Of Pages:167 | $ 4485

Male Hypogonadism Market By Hypogonadism Type (Primary Hypogonadism, Secondary Hypogonadism); By Indication (Klinefelter Syndrome, Kallmann Syndrome, Pituitary Disorders, Testicular Disorders, Other Causes); By Therapy Type (Testosterone Replacement Therapy, Gonadotropin Therapy, Other Hormonal and Adjunctive Therapies); By Route of Administration (Injectables, Topical Gels and Solutions, Oral Formulations, Transdermal Patches, Nasal Formulations, Implants and Buccal Systems); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online and Specialty Pharmacies); By Care Setting (Hospitals, Endocrinology and Urology Clinics, Specialty Men’s Health Clinics, Homecare and Telehealth); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Male Hypogonadism Market Size and How Is the Treatment Landscape Evolving?

The Global Male Hypogonadism Market was valued at USD 3.83 billion in 2025 and is projected to reach USD 5.96 billion by 2032, expanding at a CAGR of 6.52% during 2026&ndash... Read More
Published Date: SEP-2026 | No Of Pages:175 | $ 4485

Cerebral Adrenoleukodystrophy (CALD) Treatment Market By Treatment (Stem Cell Transplant, Gene Therapy, Corticosteroids, Lorenzo's Oil, Others); By Diagnosis (Blood Tests, MRI, Eye Exams, Skin Biopsy); By Symptoms (ADD, Behavior Problems, Hyperactivity, Clumsiness, Low Blood Sugar, Eye Pain, Migraine, Viral Infections, Others); By End User (Hospitals, Clinics, Others); By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Cerebral Adrenoleukodystrophy (CALD) Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Cerebral Adrenoleukodystrophy (CALD) Treatment Market was valued at USD 57.43 million in 2025 and is projected to reach USD 129.84 mi... Read More
Published Date: SEP-2026 | No Of Pages:170 | $ 4485

Achalasia Treatment Market By Treatment Type (Drug Therapy, Endoscopic Therapy, Surgical Therapy, Lifestyle Modifications); By Diagnosis Type (Esophageal Manometry, Endoscopy, Imaging Barium Swallow Test); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Achalasia Treatment Market Size and How Is the Treatment Landscape Evolving?

The Global Achalasia Treatment Market was valued at USD 618.40 million in 2025 and is projected to reach USD 1.02 billion by 2032, expanding at a CAGR of 7.43% during 2026... Read More
Published Date: SEP-2026 | No Of Pages:172 | $ 4485

Hypercalcemia Treatment Market By Treatment Type (Bisphosphonates, Denosumab, Calcitonin, Calcimimetics, Glucocorticoids, Other Calcium-Lowering Medicines); By Underlying Cause (Hypercalcemia of Malignancy, Primary Hyperparathyroidism and Parathyroid Carcinoma, Other Causes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Hypercalcemia Treatment Market and Which Therapies Are Reshaping Calcium Control?

The Global Hypercalcemia Treatment Market was valued at USD 1.28 billion in 2025 and is projected to reach USD 1.99 billion by 2032, expanding at a CAGR of 6.48% during ... Read More
Published Date: SEP-2026 | No Of Pages:165 | $ 4485

Systemic Sclerosis Treatment Market By Therapeutics (Drug Therapy, Hematopoietic Stem Cell Transplantation); By Drug Therapy (Corticosteroids, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs, Blood Pressure Medications, Proton Pump Inhibitors, TNF Inhibitors, Light Therapy, Nitroglycerin Ointment, Other Drug Therapies); By Indication (Limited Cutaneous Systemic Sclerosis, Diffuse Cutaneous Systemic Sclerosis); By Target Organ (Skin Fibrosis, Musculoskeletal Involvement, Digital Ulcers, Pulmonary Arterial Hypertension, Gastrointestinal Involvement, Pulmonary Fibrosis, Scleroderma Renal Crisis); By Route of Administration (Oral, Injectable, Topical); By Distribution Channel (Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Systemic Sclerosis Treatment Market and Which Therapies Are Reshaping the Care Pathway?

The Global Systemic Sclerosis Treatment Market was valued at USD 1.82 billion in 2025 and is projected to reach USD 3.07 billion by 2032, expanding at a CAGR of 7.... Read More
Published Date: SEP-2026 | No Of Pages:162 | $ 4485

Diabetic Macular Edema Market By Treatment Type (Anti VEGF Injections, Corticosteroids, Laser Treatment, Vitrectomy Surgery); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Diabetic Macular Edema Market Size and Why Is Revenue Shifting Toward Durable Retinal Therapy?

The Global Diabetic Macular Edema Market was valued at USD 4.75 billion in 2025 and is projected to reach USD 7.10 billion by 2032, expanding at a CAGR o... Read More
Published Date: SEP-2026 | No Of Pages:172 | $ 4485

Pompe Disease Treatment Market By Disease Type (Late-Onset Pompe Disease, Infantile-Onset Pompe Disease); By Treatment Type (Enzyme Replacement Therapy, Supportive and Symptomatic Treatment, Other Emerging Treatments); By Route of Administration (Intravenous, Oral); By End User (Hospitals, Specialty Clinics and Treatment Centers, Others); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Pompe Disease Treatment Market Size and Why Is Revenue Shifting Toward Newer ERTs?

The Global Pompe Disease Treatment Market was valued at USD 1.68 billion in 2025 and is projected to reach USD 2.51 billion by 2032, expanding at a CAGR of 5.9% duri... Read More
Published Date: SEP-2026 | No Of Pages:169 | $ 4485

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Reports by Industry

[+]Aerospace and Defense
Commercial And Civil Aviation
Defense Systems And Platforms
Space Systems And Technologies
Unmanned And Autonomous Systems
Marine And Maritime
[+]Agriculture
Crop Protection
Animal Feed And Nutrition
Farm Infrastructure
[+]Automotive
Electric And Hybrid Vehicles
Autonomous And Connected Vehicles
Automotive Components And Systems
Charging And Energy Infrastructure
Fleet Mobility And Aftermarket
[+]Chemicals and Materials
Paints Coatings And Adhesives
Specialty And Bio based Polymers
Polymers And Plastics
Advanced Materials
Metals And Alloys
Agrochemicals
Sustainable And Renewable Chemicals
Chemical Manufacturing And Processing
Catalysts And Enzymes
[+]Consumer Goods
Beauty And Personal Care
Clothing Footwear And Accessories
Homecare And Decor
Health And Wellness
Baby And Pet Care
[+]Energy and Power
Renewable Energy
Power Generation And Transmission
Energy Storage And Batteries
Oil And Gas
Electric Vehicles And Charging Infrastructure
Smart Grid And Energy Management
Clean And Renewable Fuels
[+]Equipment and Machinery
Industrial And Manufacturing Equipment
Construction And Heavy Equipment
Mining And Utility Equipment
[+]Food and Beverages
Packaged And Processed Foods
Beverages
Dairy And Dairy Alternatives
Bakery And Confectionery
Organic And Functional Foods
[+]Healthcare
Pharmaceuticals
Therapeutics
Biotechnology
Diagnostics
Medical Devices
Medical Imaging
Healthcare IT And Digital Health
Animal Health
[+]Information and Communication Technology
Communication Networks And Infrastructure
Cloud Computing And Data Centers
Cybersecurity And Data Privacy
Enterprise Software And IT Services
Emerging Technologies And Digital Transformation
[+]Semiconductor and Electronics
Semiconductor Components
Consumer Electronics
Industrial And Embedded Electronics
Communication And Networking Hardware
Electronic Manufacturing And Assembly
[+]Manufacturing and Construction
Building And Infrastructure Construction
Construction Materials And Chemicals
Advanced Manufacturing And Industry